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models and cross-sectional models. Appropriateness of
modeling in pharmacoeconomic studies and methods of
reducing bias will be presented. Finally, the importance
of disclosure of database and the actual model used will
be discussed.
WMD2
THE WHAT, HOW, AND WHY OF THE DELPHI
Downs K, Richter A
Research Triangle Institute, Research Triangle Park, NC, USA
WORKSHOP OBJECTIVE: In this workshop we will
discuss the potential uses of traditional and modified Del-
phi panels for gathering information to be used in eco-
nomic modeling, specifically, mapping medical treatment
algorithms and estimating parameters.
PARTICIPANTS WHO WOULD BENEFIT: Anyone
who develops or uses economic models and is interested
in learning more about the value of the Delphi technique.
The Delphi technique is a structured method for eliciting
expert opinions. Traditional Delphi panels consist of iter-
ative, anonymous questionnaires completed by experts.
Modified Delphi panels include a face-to-face meeting of
the participants in addition to one or more question-
naires. Both methods are intended to add structure and
credibility to the process of obtaining expert opinion for
economic modeling. The goal of this process is to obtain
results that are representative and best reflect current
clinical practices. Delphi panels can be used when pri-
mary data and published sources of information are un-
available, to support other data, or to clarify treatment
patterns which may differ from clinical trial protocols. In
this workshop, we will discuss tactics for incorporating
Delphi results in terms of developing and populating eco-
nomic models with appropriate parameter estimates. We
present the advantages and disadvantages of Delphi pan-
els versus consensus panels as well as the strengths and
weaknesses of traditional Delphi panels versus modified
Delphi panels. We also present common pitfalls that
should be avoided when using either method. We will
discuss expert selection, questionnaire development, and
panel moderation to maximize useful responses. We will
base our discussions on recent experiences with both a
traditional Delphi panel and a modified Delphi panel.
WMD3
NEW METHODS OF DATA COLLECTION IN THE 
COMMUNITY-BASED PHYSICIAN SETTING: 
PROCESS AND TECHNOLOGY
Jardina P, Irwin C
Physicians Data Corporation, Atlanta, GA, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to discuss and develop skills in formulating
new methods for clinical data collection in the commu-
nity-based physician setting.
PARTICIPANTS WHO WOULD BENEFIT: Researchers
who are interested in moving beyond administrative data
for longitudinal outcomes studies, but who are constrained
by the complexity, time, and effort of traditional clinical
data collection methods would benefit from this workshop.
Data collection is a critical component of pharmacoeco-
nomic and outcomes studies, and is often a key limiter of
study design and scope. This workshop identifies several
methods of clinical data collection in the community-
based physician setting. This information has broad util-
ity, including support of the conduct of pharmacoeco-
nomics and outcomes research. Because dictation and
transcription are the preferred means of documenting pa-
tient encounters, this workshop focuses on the role of
people, process and technology within that environment.
Will physicians change their behavior to support collec-
tion of data elements needed to conduct studies? What
types of technologies are needed to support discrete data
element capture in a dictation/transcription environment?
What is the evolving role the electronic medical record in
data collection? How are electronic data stores utilized to
cost-effectively validate source data? How can one over-
come the challenges of codifying data elements that are
collected in natural language? What is the role of manual
processes in augmenting automated data collection? The
workshop will present and explore practical strategies for
collecting, managing and reporting clinical information
in the community-based physician environment. Data
collected through September 1998 on 5865 coronary ar-
tery disease patients will be presented to demonstrate re-
sults from the techniques presented.
WMQ2
A GUIDE FOR SELECTING HEALTH OUTCOMES 
AND QUALITY OF LIFE MEASURES
Erickson P
The On-Line Guide to Quality-of-Life Assessment (OLGA), and 
Department of Health Evaluation Sciences, Hershey Medical 
Center, Penn State University, State College, PA, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop is to develop skills for evaluating alternative mea-
surement strategies for assessing health outcomes and
health-related quality of life in clinical trials and pharma-
coeconomic studies. We will present and discuss the
OLGA model for selecting an instrument or battery of in-
struments that can be used in different types of studies.
This model starts with the identification of the primary
and secondary research questions and includes important
elements in specifying the target population to assure that
the selected measures include the appropriate domains
and subdomains. Important conceptual, methodological
and practical concerns are presented within the context
of the instrument selection model.
PARTICIPANTS WHO WOULD BENEFIT: Pharmaco-
economic and health outcomes researchers who want to
increase their understanding of the issues involved in se-
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lecting meaningful and responsive quality of life instru-
ments for use in clinical trials and other evaluative studies.
Health outcomes and quality of life assessment is becom-
ing increasingly important in the evaluation of pharma-
ceutical products, in terms of labeling claims and product
promotion as well as in terms of formulary decisions.
Each of these uses requires an assessment strategy that
provides information relevant for decision-making. What
are the components of a successful strategy? How is a
given strategy evaluated to select the best for the given
evaluative study? This workshop will address these ques-
tions and introduce an analytic framework that partici-
pants can apply in their daily experience.
SESSION 3
WPE7
SCHIZOPHRENIA: HELPING THE DECISION-
MAKER TO UNDERSTAND THE IMPACTS OF 
ATYPICAL ANTIPSYCHOTICS
Mauskopf J1, David K1, Muroff M1, Grainger D2, Gibson PJ2
1Research Triangle Institute, Research Triangle Park, NC, USA; 
2Eli Lilly & Company, Indianapolis, IN, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop is to demonstrate, using a schizophrenia case study,
how prevalence-based drug value information can be pre-
sented in a format that is understandable and useful for
decision-makers.
PARTICIPANTS WHO WOULD BENEFIT: Those who
want to learn a process that will increase the likelihood
that prevalence-based drug value analyses are used by de-
cision-makers.
Although many drug value analyses have been completed
in recent years, it is not clear to what extent these analy-
ses have been used to inform decisions. In a recent paper,
Mauskopf (VH 1998) has suggested that prevalence-
based annual estimates of population and cost outcomes
would be of value to decision-makers. In this workshop,
we will take the participants through a series of activities
designed to ensure that decision-makers can understand
and use the results of prevalence-based drug value analy-
ses. We will illustrate these activities using a project that
we recently completed for schizophrenia. In this project,
we developed an interactive computer model to estimate
the impacts of the atypical anti-psychotics on patient and
family outcomes and healthcare costs for a population of
schizophrenia patients. The project included three main
activities: 1) develop a preliminary model; 2) present the
model to decision-makes to determine its value to them;
and 3) revise the model based on decision-maker com-
ments and create an interactive computer version of the
model. We will show the workshop participants how we
presented our model to the decision-makers. We will
summarize the decision-makers responses to the presen-
tation. We will then lead the workshop participants in a
discussion about the range of possible responses to these
comments and the trade-offs between 1) keeping a model
well grounded in published literature; and 2) extrapolating
information to address outcomes that are important to de-
cision-makers, but not well researched. We will conclude
the workshop by describing how we modified the prelimi-
nary model in response to the decision-makers’ comments
and by showing the final interactive computer model.
WPE8
DESIGNING NATURALISTIC OUTCOMES 
TRIALS THAT ARE APPLICABLE TO THE “REAL 
WORLD” OF CLINICAL PRACTICE
Tunis SL, Melfi CA, Robinson R
Eli Lilly and Company, Indianapolis, IN, USA
WORKSHOP OBJECTIVE: To highlight design features
that characterize state-of-the-art studies evaluating out-
comes of competing pharmacotherapies, balancing the need
to maintain internal validity with the goal of providing in-
formation that can be applied to the “real world” of clinical
practices.
PARTICIPANTS WHO WOULD BENEFIT: 1) Out-
comes researchers, statisticians, health economists, and
others who wish to expand beyond the traditional clini-
cal trial design; and 2) clinicians, healthcare organiza-
tions, and others who wish to learn more about how to
make informed decisions based on comparative cost and
effectiveness claims.
Various methodological issues are critical in the design of
naturalistic outcomes trials. These include how narrowly
(or broadly) to define the patient population, whether or
not to “blind” the study, how much physician discretion
to allow in treating patients, and how to obtain and ana-
lyze data on patients who switch from their originally-as-
signed medication (or on patients who discontinue medi-
cation). Additionally, the definition of comparator(s) and
the appropriate time horizon of the study are important.
These and other issues will be discussed and illustrated
through examples of two randomized naturalistic trials de-
signed by the workshop leaders and colleagues. One study
is designed to answer the question of whether using an
atypical antipsychotic agent as first-line therapy is more ef-
fective and less costly than requiring a patient to first fail
on conventional medications. The other study is designed
to determine how three different selective serotonin re-
uptake inhibitors compare in terms of various outcome
measures including patient adherence, quality of life, and
resource utilization. The authors will discuss the decisions
made in designing these trials and the implications of these
decisions for data analysis and interpretation of findings.
WPE10
GUIDELINES FOR THE ECONOMIC 
EVALUATION OF PHARMACEUTICALS: 
CURRENT USE AND EMERGING TRENDS
Munro V1, Geneste B2, Luce B3
1MEDTAP International, London, UK; 2Rhône Poulenc Rorer, 
Paris, France; 3MEDTAP International, Bethesda, MD, USA
